AGEN:NSD-Agenus Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 2.40

Change

+0.05 (+2.13)%

Market Cap

USD 0.38B

Volume

2.09M

Average Target Price

USD 6.00 (+150.00%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, LAG-3, and others. In addition, the company develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neoantigen; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neoepitopes. Further, it develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Additionally, the company engages in the development of CTLA-4 and PD-1 antagonists; and anti-CTLA-4, CD137, and TIGIT antibodies, as well as various multi-specific antibodies that are under various stages of development. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-03-30 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+14.68 (+6.76%)

USD57.85B 49.47 37.66
REGN Regeneron Pharmaceuticals, Inc

+23.48 (+5.22%)

USD49.46B 24.35 18.92
SGEN Seattle Genetics, Inc

+6.02 (+5.51%)

USD18.82B N/A -91.93
ALXN Alexion Pharmaceuticals, Inc

+3.25 (+3.87%)

USD18.60B 7.85 7.48
INCY Incyte Corporation

+3.21 (+4.65%)

USD14.95B 33.64 27.08
BMRN BioMarin Pharmaceutical Inc

+2.98 (+3.75%)

USD14.84B N/A 31,783.95
GMAB Genmab A/S

+0.38 (+1.89%)

USD12.83B N/A N/A
BNTX BioNTech SE

+7.00 (+12.73%)

USD12.47B N/A N/A
ALNY Alnylam Pharmaceuticals, Inc

+4.63 (+4.44%)

USD11.78B N/A -11.75
GLPG Galapagos NV

+8.24 (+4.52%)

USD11.64B 72.40 N/A

ETFs Containing AGEN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -41.03% 27% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -41.03% 27% F 25% F
Trailing 12 Months  
Capital Gain -19.19% 63% D 59% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.19% 63% D 56% F
Trailing 5 Years  
Capital Gain -53.22% 54% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -53.22% 53% F 29% F
Average Annual (5 Year Horizon)  
Capital Gain -7.63% 42% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.63% 42% F 20% F
Risk Return Profile  
Volatility (Standard Deviation) 34.14% 65% D 38% F
Risk Adjusted Return -22.35% 41% F 22% F
Market Capitalization 0.38B 67% D+ 62% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -20.33 88% B+ 91% A-
EV/EBITDA -6.28 75% C 83% B
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 34.73% 92% A- 94% A
Return on Assets -27.56% 55% F 17% F
Debt to Equity Ratio -5.94% 85% B 92% A-
Technical Ratios  
Short Ratio 3.74 48% F 38% F
Short Percent 11.12% 35% F 25% F
Beta 2.55 11% F 6% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.